Latest Insider Transactions at Biogen Inc. (BIIB)
This section provides a real-time view of insider transactions for Biogen Inc. (BIIB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BIOGEN INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BIOGEN INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 27
2021
|
Michel Vounatsos Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,343
+24.21%
|
-
|
|
Jan 27
2021
|
Alfred Sandrock Head of Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
3,728
+18.17%
|
-
|
|
Jan 27
2021
|
Ginger Gregory EVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
2,558
+26.08%
|
-
|
|
Jan 27
2021
|
Alphonse Galdes EVP Pharmaceutical Oper & Tech |
BUY
Grant, award, or other acquisition
|
Direct |
818
+19.19%
|
-
|
|
Jan 27
2021
|
Susan H Alexander EVP Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,545
+9.95%
|
-
|
|
Dec 03
2020
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
22
-5.57%
|
$5,368
$244.09 P/Share
|
|
Dec 03
2020
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
74
+15.78%
|
-
|
|
Dec 01
2020
|
Chirfi Guindo Head of Glob Prod Strat & Com |
SELL
Payment of exercise price or tax liability
|
Direct |
562
-7.17%
|
$136,566
$243.16 P/Share
|
|
Dec 01
2020
|
Chirfi Guindo Head of Glob Prod Strat & Com |
BUY
Exercise of conversion of derivative security
|
Direct |
481
+10.72%
|
-
|
|
Nov 30
2020
|
Michel Vounatsos Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
3,100
+8.18%
|
$747,100
$241.31 P/Share
|
|
Nov 04
2020
|
Alfred Sandrock Head of Research & Development |
SELL
Open market or private sale
|
Direct |
1,500
-10.3%
|
$525,000
$350.0 P/Share
|